FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899034031> ?p ?o ?g. }

• W2899034031 abstract "Abstract Background Patients with hematologic malignancies treated with anticancer immunosuppressive therapies (ITs) are at increased risk of herpes zoster (HZ). In a previous report of this phase 3, observer-blind, multicenter trial (NCT01767467), the adjuvanted recombinant zoster vaccine (RZV) was shown to be immunogenic and well-tolerated in ≥18 years of age patients with hematologic malignancies who completed or were undergoing anticancer IT.1 Here we report end-of-study results from the same trial. Methods Participants were randomized 1:1 to receive 2 doses of RZV or placebo (PL) 1–2 months apart, either ≥10 days before or after a cancer therapy cycle, or 10 days to 6 months after cancer therapy ended. Humoral and cell-mediated immune (CMI) responses were evaluated at 1 month and 12 months post-dose 2 (month 2 and month 13, respectively). Confirmatory objectives were to evaluate humoral response rate to RZV and to compare humoral immune responses to RZV and PL at month 2 excluding either subjects with chronic lymphocytic leukemia and non-Hodgkin B-cell lymphoma (NHBCL), or only those with NHBCL. Efficacy against HZ was explored in a post-hoc analysis of confirmed HZ cases. Solicited and unsolicited adverse events (AEs) were recorded for 7 and 30 days after each dose, respectively. Serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were recorded throughout the study. Results Of the 562 (RZV: 283, PL: 279) treated participants, 415 (RZV: 217, PL: 198)/310 (RZV: 168, PL: 142) were included in the according-to-protocol (ATP) cohort for humoral immunogenicity/immune persistence. The ATP sub-cohort for CMI included 132 (RZV: 69, PL: 63) participants at month 2 and 100 (RZV: 54, PL: 46) at month 13. All confirmatory immunogenicity objectives were met (Table 1). RZV efficacy against HZ, assessed post-hoc, was 87.2% (Table 2). RZV was more reactogenic than PL. The occurrence of unsolicited AEs, SAEs, and pIMDs was similar between the study groups (Table 3). Conclusion RZV induced robust humoral and cellular immune responses and showed an effect in the reduction of HZ incidence in patients with hematologic malignancies who completed or were undergoing anticancer IT. No safety concerns were identified. Reference 1. Oostvogels et al. IDWeek2017, abs 1344. Funding. GlaxoSmithKline Biologicals SA. Disclosures A. F. Dagnew, GSK: Employee and Shareholder, Salary. J. Murphy, GSK: Investigator, Research support. S. A. McNeil, GSK group of companies: Grant Investigator, Research grant and Research support. B. Salaun, GSK group of companies: Employee and Shareholder, Salary. E. Di Paolo, GSK group of companies: Employee, Salary. L. Campora, GSK group of companies: Employee and Shareholder, Salary. M. López-Fauqued, GSK group of companies: Employee, Salary. M. El Idrissi, GSK group of companies: Employee, Salary. A. Schuind, GSK: Employee, Salary. T. C. Heineman, GSK group of companies: Consultant, Employee and Shareholder, Consulting fee and Salary. P. Van Den Steen, GSK: Employee and Shareholder, Restricted shares and Salary. L. Oostvogels, GSK: Employee, Salary and Stock and stock options." @default.
• W2899034031 created "2018-11-09" @default.
• W2899034031 creator A5002078991 @default.
• W2899034031 creator A5005056682 @default.
• W2899034031 creator A5007727405 @default.
• W2899034031 creator A5010551056 @default.
• W2899034031 creator A5012620466 @default.
• W2899034031 creator A5016981842 @default.
• W2899034031 creator A5026192090 @default.
• W2899034031 creator A5028114227 @default.
• W2899034031 creator A5029116843 @default.
• W2899034031 creator A5030960735 @default.
• W2899034031 creator A5033432239 @default.
• W2899034031 creator A5035905929 @default.
• W2899034031 creator A5040511970 @default.
• W2899034031 creator A5041537315 @default.
• W2899034031 creator A5047626220 @default.
• W2899034031 creator A5051915476 @default.
• W2899034031 creator A5058719258 @default.
• W2899034031 creator A5059940446 @default.
• W2899034031 creator A5073159044 @default.
• W2899034031 creator A5076735212 @default.
• W2899034031 creator A5077318648 @default.
• W2899034031 creator A5079128178 @default.
• W2899034031 creator A5084123217 @default.
• W2899034031 creator A5090991647 @default.
• W2899034031 creator A5091020071 @default.
• W2899034031 date "2018-11-01" @default.
• W2899034031 modified "2023-10-18" @default.
• W2899034031 title "149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial" @default.
• W2899034031 doi "https://doi.org/10.1093/ofid/ofy209.019" @default.
• W2899034031 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6252456" @default.
• W2899034031 hasPublicationYear "2018" @default.
• W2899034031 type Work @default.
• W2899034031 sameAs 2899034031 @default.
• W2899034031 citedByCount "3" @default.
• W2899034031 countsByYear W28990340312019 @default.
• W2899034031 countsByYear W28990340312023 @default.
• W2899034031 crossrefType "journal-article" @default.
• W2899034031 hasAuthorship W2899034031A5002078991 @default.
• W2899034031 hasAuthorship W2899034031A5005056682 @default.
• W2899034031 hasAuthorship W2899034031A5007727405 @default.
• W2899034031 hasAuthorship W2899034031A5010551056 @default.
• W2899034031 hasAuthorship W2899034031A5012620466 @default.
• W2899034031 hasAuthorship W2899034031A5016981842 @default.
• W2899034031 hasAuthorship W2899034031A5026192090 @default.
• W2899034031 hasAuthorship W2899034031A5028114227 @default.
• W2899034031 hasAuthorship W2899034031A5029116843 @default.
• W2899034031 hasAuthorship W2899034031A5030960735 @default.
• W2899034031 hasAuthorship W2899034031A5033432239 @default.
• W2899034031 hasAuthorship W2899034031A5035905929 @default.
• W2899034031 hasAuthorship W2899034031A5040511970 @default.
• W2899034031 hasAuthorship W2899034031A5041537315 @default.
• W2899034031 hasAuthorship W2899034031A5047626220 @default.
• W2899034031 hasAuthorship W2899034031A5051915476 @default.
• W2899034031 hasAuthorship W2899034031A5058719258 @default.
• W2899034031 hasAuthorship W2899034031A5059940446 @default.
• W2899034031 hasAuthorship W2899034031A5073159044 @default.
• W2899034031 hasAuthorship W2899034031A5076735212 @default.
• W2899034031 hasAuthorship W2899034031A5077318648 @default.
• W2899034031 hasAuthorship W2899034031A5079128178 @default.
• W2899034031 hasAuthorship W2899034031A5084123217 @default.
• W2899034031 hasAuthorship W2899034031A5090991647 @default.
• W2899034031 hasAuthorship W2899034031A5091020071 @default.
• W2899034031 hasBestOaLocation W28990340311 @default.
• W2899034031 hasConcept C121608353 @default.
• W2899034031 hasConcept C126322002 @default.
• W2899034031 hasConcept C142724271 @default.
• W2899034031 hasConcept C143998085 @default.
• W2899034031 hasConcept C168563851 @default.
• W2899034031 hasConcept C197934379 @default.
• W2899034031 hasConcept C203014093 @default.
• W2899034031 hasConcept C204787440 @default.
• W2899034031 hasConcept C22070199 @default.
• W2899034031 hasConcept C27081682 @default.
• W2899034031 hasConcept C2780868878 @default.
• W2899034031 hasConcept C535046627 @default.
• W2899034031 hasConcept C71924100 @default.
• W2899034031 hasConcept C8891405 @default.
• W2899034031 hasConceptScore W2899034031C121608353 @default.
• W2899034031 hasConceptScore W2899034031C126322002 @default.
• W2899034031 hasConceptScore W2899034031C142724271 @default.
• W2899034031 hasConceptScore W2899034031C143998085 @default.
• W2899034031 hasConceptScore W2899034031C168563851 @default.
• W2899034031 hasConceptScore W2899034031C197934379 @default.
• W2899034031 hasConceptScore W2899034031C203014093 @default.
• W2899034031 hasConceptScore W2899034031C204787440 @default.
• W2899034031 hasConceptScore W2899034031C22070199 @default.
• W2899034031 hasConceptScore W2899034031C27081682 @default.
• W2899034031 hasConceptScore W2899034031C2780868878 @default.
• W2899034031 hasConceptScore W2899034031C535046627 @default.
• W2899034031 hasConceptScore W2899034031C71924100 @default.
• W2899034031 hasConceptScore W2899034031C8891405 @default.
• W2899034031 hasLocation W28990340311 @default.
• W2899034031 hasLocation W28990340312 @default.
• W2899034031 hasLocation W28990340313 @default.
• W2899034031 hasOpenAccess W2899034031 @default.
• W2899034031 hasPrimaryLocation W28990340311 @default.
• W2899034031 hasRelatedWork W2045254302 @default.
• W2899034031 hasRelatedWork W2899034031 @default.

• next